Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 4Relapsed Pediatric Solid Tumor 2Refractory Solid Tumors 2Unspecified Adult Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor - Protocol Specific 1Solid Tumours 1Solid Tumor, Adult 1Solid Tumor 1Refractory or Recurrent Solid Tumor 1Advanced Cancers 1

Interventions

pembrolizumab 7Radiotherapy 3Proton Therapy 3Interleukin-2 3Cyclophosphamide 3spartalizumab 2fludarabine 2Rosuvastatin Calcium 2Paclitaxel 2Ipilimumab 2Immune Checkpoint Inhibitors 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2toripalimab 1tislelizumab 1sotorasib 1peposertib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1niraparib 1neotil 1necitumumab 1mirdametinib 1leronlimab 1lenvatinib 1atezolizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor, Adult × pazopanib × Other solid neoplasm × Clear all
NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Tianjin Medical University Second Hospital

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡